Get to know our clinical trials
Study to evaluate maintenance with bortezomib and daratumumab (V-Dara) in newly diagnosed patients with multiple myeloma (MM) who are not eligible for autologous stem cell transplantation (ASCT)
THE OVERALL OBJECTIVE IS TO EVALUATE THE EFFECTIVENESS OF MAINTENANCE WITH BORTEZOMIB AND DARATUMUMAB AFTER INDUCTION (PRIOR USE) WITH BORTEZOMIB, MELPHALAN AND PREDNISONE AND DARATUMUMUMAB. SEVERAL PARAMETERS WILL BE COLLECTED FROM YOUR CLINICAL HISTORY ACCORDING TO THE USUAL PRACTICES IN THE ONCOHEMATOLOGY UNIT OF THE HOSPITAL WHERE YOU ARE BEING TREATED.
Technical Summary
- PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE MAINTENANCE WITH BORTEZOMIB AND DARATUMUMAB (V-DARA) AFTER INDUCTION WITH BORTEZOMIB, MELPHALAN, PREDNISONE, AND DARATUMUMUMAB (VMP-DARA) IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA (MM) WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): REAL ALCYONE-OPTIMIZED EVIDENCE DATA. IMMUNOTHERAPY
- Code EudraCT: ..
- Protocol number: GEM-OPTIMAL
- Promoter: Fundación Pethema
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.